Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 12.36% since last year same period to $259.6Mn in the Q4 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 3.67% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 213.87% since last year same period to $143.74Mn in the Q4 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 338.71% jump in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin jumped 179.34% since last year same period to 55.37% in the Q4 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 323.16% jump in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.05 - a -77.17% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.05.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) jumped 207.14% since last year same period to 0.86 in the Q4 2024. This indicates that the Acadia Pharmaceuticals Inc. has generated 207.14% annual rate of jump in its earning per share (EPS) in the last 4 quarters.